Here are the top 5 biosimilar articles for the week of November 8, 2021.
Hi, I’m Matthew Gavidia for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of November 8, 2021.
Number 5: Pfizer has indicated an intention to seek interchangeable status for its adalimumab biosimilar Abrilada, which is scheduled to launch in the United States in 2023.
Number 4: The month of October brought the second interchangeable biosimilar approval in the United States (adalimumab, Cyltezo), and Roche won FDA approval for an ocular implantable ranibizumab device, which could be a game changer in the field of ophthalmology.
Number 3: Janet Woodcock, MD, acting commissioner of the FDA, says it’s back to business for the FDA when it comes to biosimilars. COVID-19 distractions have diminished and the agency can focus on applications and factory inspections, she explains.
Number 2: Sarfaraz K. Niazi, PhD, is a member of the Advisory Board for The Center for Biosimilars® and in a column he explains one of his “biosimilar” diversions: making whiskey in the lab that tastes like the real thing, although it’s more affordable and potentially more accessible.
Number 1: Ali Ahmed, senior vice president of biosimilars for Fresenius Kabi, explains the company’s bid for a seat at the global biosimilars table. In particular, Ahmed talks about the company’s pegfilgrastim and tocilizumab biosimilar candidates, for the treatment of neutropenia and rheumatoid arthritis, respectively.
To read all of these articles and more, visit centerforbiosimilars.com.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: BI Cyltezo Partnership; Europe Ustekinumab Launch; Mexico Biosimilar Approval
July 24th 2024Boehringer Ingelheim (BI) partners with GoodRx to offer its unbranded adalimumab biosimilar to patients at an exclusive low price; a new ustekinumab biosimilar launches in Europe; and Mexican officials approve a bevacizumab biosimilar.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Real-World Study: No Increase in Health Resource Costs After Infliximab Biosimilar Introduction
July 20th 2024Although biosimilars reduce drug purchasing costs for hospitals, it’s unclear whether those savings might be offset by increased health resource utilization following a non-medical switching initiative.